Highly Efficient Labeling of Human Lung Cancer Cells Using Cationic Poly-l-lysine-Assisted Magnetic Iron Oxide Nanoparticles
- 2.9k Downloads
Cell labeling with magnetic iron oxide nanoparticles (IONPs) is increasingly a routine approach in the cell-based cancer treatment. However, cell labeling with magnetic IONPs and their leading effects on the biological properties of human lung carcinoma cells remain scarcely reported. Therefore, in the present study the magnetic γ-Fe2O3 nanoparticles (MNPs) were firstly synthesized and surface-modified with cationic poly-l-lysine (PLL) to construct the PLL-MNPs, which were then used to magnetically label human A549 lung cancer cells. Cell viability and proliferation were evaluated with propidium iodide/fluorescein diacetate double staining and standard 3-(4,5-dimethylthiazol-2-diphenyl-tetrazolium) bromide assay, and the cytoskeleton was immunocytochemically stained. The cell cycle of the PLL-MNP-labeled A549 lung cancer cells was analyzed using flow cytometry. Apoptotic cells were fluorescently analyzed with nuclear-specific staining after the PLL-MNP labeling. The results showed that the constructed PLL-MNPs efficiently magnetically labeled A549 lung cancer cells and that, at low concentrations, labeling did not affect cellular viability, proliferation capability, cell cycle, and apoptosis. Furthermore, the cytoskeleton in the treated cells was detected intact in comparison with the untreated counterparts. However, the results also showed that at high concentration (400 µg mL−1), the PLL-MNPs would slightly impair cell viability, proliferation, cell cycle, and apoptosis and disrupt the cytoskeleton in the treated A549 lung cancer cells. Therefore, the present results indicated that the PLL-MNPs at adequate concentrations can be efficiently used for labeling A549 lung cancer cells and could be considered as a feasible approach for magnetic targeted anti-cancer drug/gene delivery, targeted diagnosis, and therapy in lung cancer treatment.
KeywordsMagnetic labeling Iron oxide nanoparticles Poly-l-lysine Human A549 lung cancer cells Cancer treatment
Lung cancer is the most common cause of cancer-related deaths worldwide [1, 2]. According to the US National Cancer Institute, approximately 226, 160 new lung cancers were diagnosed and 160, 340 lung cancer-related deaths were recorded in the US at the end of 2012. Despite advances in cancer research, the discovery of lung cancer biomarkers has not significantly improved conventional treatments in recent years . Therefore, the development of novel approaches for the detection of early lung cancer-specific markers for personalized treatment is urgently needed to increase patient survival in lung cancer treatment. Nanotechnology has provided new perspectives for molecular detection, cellular imaging, and screening in cancer treatment. Despite the fact that nanotechnology can provide sensitive and specific information from lung cancer patients, the selective delivery of anti-cancer drugs to tumor sites in lung cancer treatment is also highly desirable [4, 5].
Magnetic nanoparticles (IONPs) (mostly γ-Fe2O3 and Fe3O4) have received an increasing interest in biomedical applications because of their low toxicity, outstanding biocompatibility, and superparamagnetic properties applicable in cell labeling and separation [6, 7], cell imaging [8, 9], cell-based therapy [10, 11], magnetofection , and tissue engineering and repair [13, 14], among other uses. Further, IONPs have a large surface area engineered with a number of functional groups capable of cross-linking to tumor-targeting ligands, such as antibodies, peptides, or small molecules, for diagnostic imaging or delivery of therapeutic agents [15, 16, 17]. IONPs for cell labeling have been widely used to isolate cells of interest from a heterogeneous population within a magnetic field via phenotypic markers tagged with magnetic particles [18, 19]. The labeling of cells with IONPs allows to noninvasively monitor the migration, biodistribution, and behavior of targeted cells. Therefore, the efficient magnetic labeling of targeted cells offers promising new approaches in cell-based therapy with great potential for cancer treatment .
The magnetic labeling of cells can be performed following either of two approaches: (i) the direct attachment of magnetic particles to the cell surface  or (ii) the receptor-mediated or transfection agent-mediated endocytosis pathway which internalizes biocompatible magnetic particles . A variety of competent ligands and target agents conjugated onto nanoparticle surfaces, including monoclonal antibodies, transferrin, and folic acid, have been used to target cell surfaces [22, 23, 24]. The endocytosis pathway, which involves the transfection of IONPs into cells, requires a high rate of nanoparticle internalization by the cells. However, both the cell membrane and IONPs are usually negatively charged, leading to the inefficient labeling of targeted cells because of repulsive electric interactions. Therefore, the complexing of positively charged transfection agents, such as polyethylenimine [25, 26], lipofectamine [27, 28], poly-l-lysine (PLL) [29, 30], and protamine sulfate [31, 32], is often introduced to enhance cell labeling efficiency through favorable electrostatic interactions between the target cells and transfection agent-modified IONPs. PLL is commonly used to enhance cell adhesion on the surface of culture dishes and is a potent modifier for IONPs . A PLL coating on IONPs could lead to improved electrostatic binding on target cells and thus enhance cellular uptake.
In the present study, the PLL-modified MNPs were constructed to label human A549 lung cancer cells. Compared with previous studies [34, 35], the present study attempted to use cationic transfection agent PLL coupled with MNPs to enhance the cellular uptake of nanoparticles in human A549 lung cancer cells. Furthermore, the effects of magnetic labeling on the biological properties of A549 lung cancer cells, including cell viability, proliferation capacity, cytoskeletal disruption, cell cycle, and apoptosis, were investigated separately. The morphology and structure of the PLL-MNPs were characterized by transmission electron microscopy (TEM), X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR), and vibrating sample magnetometry. The iron uptake of magnetically labeled A549 lung cancer cells was confirmed with histological Prussian blue staining. The viability of magnetically labeled A549 lung cancer cells was assessed by fluorescein diacetate (FDA) and propidium iodide (PI) double staining. The cytoskeletal disruption and apoptosis rate of magnetically labeled A549 lung cancer cells was assayed by rhodamine-conjugated phalloidin and fluorescent bisbenzimide dye (Hoechst H33258). The cell cycle of the labeled A549 lung cancer cells was analyzed by flow cytometry. Taken together, this study provides insights into the effects of magnetic labeling on the biological properties of A549 lung cancer cells and facilitates the MRI-assisted tracking and in vivo monitoring of their survival, migration, and transformation, which would be of great interest for targeted lung cancer cell treatment.
2.1 Reagents and Materials
The superparamagnetic γ-Fe2O3 NPs utilized in this study were prepared from magnetite (Fe3O4) according to the methods proposed elsewhere [36, 37]. The human lung alveolar carcinoma epithelial cells (A549) were obtained from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China). The cell culture medium and fetal bovine serum (FBS) were purchased from Gibco Invitrogen Corporation (CA, USA). PLL (M w = 338,100), 3-(4,5-dimethylthiazol-2-diphenyl-tetrazolium) bromide (MTT), potassium ferrocyanide (Perls reagent), FDA, PI, RNase, Hoechst H33258, dimethyl sulfoxide (DMSO), Triton X-100 solution, glutaraldehyde, and paraformaldehyde were purchased from Sigma-Aldrich (St. Louis, MO, USA). Neutral red was obtained from Beyotime Biotech (Jiangsu, China). Fluorescent dye 4,6-diamidino-2-phenylindole (DAPI) was purchased from Molecular Probes Inc. (Eugene, OR, USA). Rhodamine phalloidin was obtained from Cytoskeleton Inc. (Denver, CO, USA). Other reagents and chemicals were purchased from local commercial suppliers and were of analytical reagent grade, unless otherwise stated. Deionized water (Milli-Q, Millipore, Bedford, MA, USA) was used to prepare aqueous solutions.
2.2 Principle of A549 Lung Cancer Cell Labeling with PLL-Modified MNPs
2.3 Synthesis and Characterization of the PLL-MNPs
MNPs used in the study were prepared and characterized as previously described elsewhere [36, 37], and the PLL modification was then performed to enhance cellular uptake to NPs . Briefly, 3.6 mL of MNPs (2 mg mL−1) were mixed with 3.6 mL of serum-free RPMI-1640 medium, followed by the addition of 0.8 mL of PLL (0.45 mg mL−1). The solution containing MNPs and PLL was then incubated with low-speed stirring for 2 h at 200 rpm, and the prepared PLL-modified MNPs were washed to remove residual PLL with serum-free RPMI-1640 medium under the magnetic field for three times. Finally, the PLL-MNPs were vacuum desiccated and stored at 4 °C until further use.
The morphology of MNPs and PLL-MNPs was characterized by TEM using a Hitachi H-600 microscope (Japan). The crystal structure of MNPs was characterized by an X-ray diffractometer (Philips D/Max-2500, Holland) using a monochromatized X-ray beam with nickel-filtered Cu-Kα radiation. FT-IR (Nicolet NEXUS 670, USA) was performed to record the spectra of MNPs and PLL-MNPs. Magnetic measurements of the PLL-MNPs were performed on a vibrating sample magnetometer (Lakeshore-7304, USA) by changing H between +1375 and −1375 Oe.
2.4 Cell Culture
The human A549 lung cancer cells were routinely cultured in RPMI-1640 medium supplemented with 10 % (v/v) heat-inactivated FBS, 1 % l-glutamine, 1 % penicillin (100 U mL−1), and 1 % streptomycin (100 µg mL−1) in a humidified incubator at 37 °C in the presence of 5 % CO2. The cells were regularly monitored using an inverted light microscope, and the culture medium was changed every 2 days. The cells were normally passaged in 1:3 ratios every 3 days to maintain an exponential growth phase.
2.5 Labeling of A549 Lung Cancer Cells with the PLL-MNPs
The A549 cells at the exponential growth phase were treated with 0.25 % trypsin in Ca+- and Mg+-free phosphate-buffered saline (PBS, pH 7.4) for 5 min at 37 °C to prepare a cell suspension. The cells were counted using a regular hemocytometer and then seeded at a density of 2 × 104 cells/well in a 24-well plate. Different concentrations of the PLL-MNPs were then added to the 24-well plates separately. The culture medium was discarded after incubation for 48 h, and the PLL-MNP-labeled A549 cells were then incubated with a mixture (50:50, v/v) of 2 % potassium ferrocyanide (Perls reagent) and 2 % hydrochloric acid for 30 min following fixation with 4 % paraformaldehyde. Counterstaining was performed by incubating the cells with neutral red for 2 min. Unlabeled A549 cells were used as the control.
2.6 A549 Cell Proliferation Capacity Assay after PLL-MNP Labeling
The standard MTT method was used to evaluate the proliferation capacity of A549 lung cancer cells after PLL-MNP labeling. The A549 cells were harvested to prepare a cell suspension at the exponential growth phase and then seeded at a density of 1 × 104 cells/well in a 96-well microwell plate. The PLL-MNPs were added to the microwell plates at final concentrations ranging from 25 to 400 µg mL−1. The culture medium was removed after incubation for 48 h and 200 µL of the prepared MTT solution (final concentration: 0.5 mg mL−1) was then added and incubated for 4 h, followed by the addition of 150 µL DMSO. Finally, the absorbance of the prepared solutions was measured at 570 nm on a microplate spectrophotometer (Bio Tek Instrument Inc., USA). Unlabeled A549 cells were used as the control.
2.7 A549 Lung Cancer Cell Viability Assay after PLL-MNP Labeling
The cell viability of PLL-MNP-labeled A549 cells was assessed by the FDA and PI double-staining protocol [39, 40]. The A549 cells were seeded and incubated for 12 h at a density of 2 × 104 cells/well in a 24-well plate. The PLL-MNPs were added to the plate at final concentrations ranging from 25 to 400 µg mL−1. Subsequently, the FDA (final concentration: 1 μg mL−1) and PI solutions (final concentration: 20 μg mL−1) were successively introduced into the culture plates. The cellular viability was then analyzed by counting the live and dead cells after incubation for 10 min at room temperature. The living cells were stained green by FDA, whereas the dead cells were stained red by the fluorescent PI dye. The samples were analyzed with an inverted fluorescence microscope equipped with a high-resolution CCD camera. Unlabeled A549 cells were used as the control.
2.8 Immunofluorescent Staining of Actin Cytoskeleton
The morphology and F-actin cytoskeletal structure of A549 cells exposed to varying concentrations of the PLL-MNPs were investigated. Actin cytoskeleton staining was performed using rhodamine phalloidin following the kit’s protocol with minor modifications. Briefly, the A549 cells were seeded in the PLL-coated 24-well plates, cultured for 12 h, and then treated with the PLL-MNPs in an RPMI-1640 medium. The PLL-MNP-labeled A549 cells were then fixed with 2.5 % glutaraldehyde for 10 min at room temperature, and 0.5 % Triton X-100 solution in PBS was introduced to permeabilize the cells by culturing for 5 min at room temperature. The permeabilized cells were washed with PBS (pH 7.4) for three times and then refilled with 200 µL of 100 nM rhodamine phalloidin. Sequentially, the cells were incubated in the dark for 30 min at room temperature. The cells were counterstained with DAPI dye to reveal nuclei. Finally, the samples were observed under an inverted fluorescence microscope equipped with a high-resolution CCD camera.
2.9 Cell Cycle Analysis of PLL-MNP-Labeled A549 Lung Cancer Cells
The cell cycle of PLL-MNP-labeled A549 cells was analyzed by flow cytometry. The PLL-MNP- treated A549 cells were firstly harvested and dissociated into a single-cell suspension, and 1 × 106 cells were resuspended in 500 µL of PBS solution after washing three times. The A549 cells were then fixed by adding 2 mL of 70 % ice-cold ethanol, followed by overnight incubation at 4 °C. The prepared cell suspension was then centrifuged to discard the fixative, resuspended in 2 mL of PBS solution, and filtered using a 200-mesh cell screen. The pelleted cells were resuspended in 1 mL of 50 µg mL−1 PI solution containing 20 µg mL−1 RNase for cell staining. The A549 cells were incubated in the dark at 4 °C for 1 h, analyzed using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA), and analyzed using CELLQUEST software (BD Biosciences). The untreated A549 cells were used as controls.
2.10 Fluorescent Staining of Apoptotic Cells
To visualize apoptotic cells, the PLL-MNP-labeled A549 cells were fixed with 4 % paraformaldehyde for 15 min and then stained with Hoechst H33258 solution (concentration: 2 µg mL−1) for 10 min at room temperature. The stained cells were rinsed with PBS three times and then observed via an inverted fluorescence microscope equipped with a high-resolution CCD camera. Untreated A549 cells were used as the control.
A transmission electron microscope (TEM, Hitachi H-600, Japan) was employed to characterize the morphology and structure of the prepared MNPs and PLL-MNPs. The crystal structure of MNPs was analyzed with an X-ray diffractometer (XRD, Philips D/Max-2500, Holland) using a monochromatic X-ray beam with nickel-filtered Cu-Kα radiation. Magnetic measurements of PLL-MNPs were carried out on a vibrating sample magnetometer (LAKESHORE-7304, USA) by changing H between +1375 and −1375 Oe. Fluorescence images were acquired using an inverted fluorescence microscope (Eclipse TE 2000-U, Nikon, Kyoto, Japan) equipped with a high-resolution CCD camera (CV-S3200, JAI Co., Japan). The cell cycle of the PLL-MNP-labeled A549 cells were analyzed using FACS Calibur flow cytometer (BD Biosciences, San Jose, CA).
2.12 Image Acquisition and Analysis
Bright-field and fluorescence images were acquired using an inverted fluorescence microscope (Eclipse TE 2000-U, Nikon, Kyoto, Japan) equipped with a CCD camera (CV-S3200, JAI Co., Japan). Software Image-Pro Plus® 6.0 (Media Cyternetics) and SPSS 12.0 (SPSS Inc.) were used to perform image analysis and statistical data analysis, respectively. The quantitative data are presented as mean ± standard deviation for each experiment. All experiments were performed with at least three replicates, and the results presented were obtained from representative experiments.
3 Results and Discussion
3.1 Synthesis and Characterization of MNPs and PLL-MNPs
3.2 Labeling of A549 Lung Cancer Cells with the PLL-MNPs
3.3 Proliferation Capacity of PLL-MNP-Labeled A549 Lung Cancer Cells
3.4 Cell Viability of PLL-MNP-Labeled A549 Lung Cancer Cells
3.5 Actin Cytoskeleton of PLL-MNP-Labeled A549 Lung Cancer Cells
3.6 Effects of PLL-MNP Labeling on the Cell Cycle of A549 Cells
3.7 Apoptosis Assay
Cell apoptosis is a distinct process of programed cell death and plays an important role in carcinogenesis and cancer treatment. Apoptosis is generally characterized by distinct morphological characteristics of related cells, which usually include blebbing, cell shrinkage, nuclear fragmentation, chromatin condensation, and chromosomal DNA fragmentation [48, 49]. In contrast, tumor cells are characterized by their ability to bypass apoptosis. Thus, apoptosis is commonly used as a vehicle for targeted cell treatment in cancer therapy [50, 51]; medications used to induce apoptosis of tumor cells are a major focus of cancer treatment.
In the present study, the PLL-MNPs were fabricated with excellent superparamagnetic properties and were used to label human A549 lung cancer cells. The effects of magnetic labeling on the biological behavior of A549 lung cancer cells were also analyzed. The results showed that, in comparison with previous studies, the fabricated PLL-MNPs could enhance the cellular uptake in A549 lung cancer cells, the low concentrations of the PLL-MNPs used to label cells did not affect the cell proliferation, viability, and cytoskeleton (F-actin) organization in comparison with unlabeled counterparts, and that cell apoptosis was slightly affected by high concentrations of the PLL-MNPs. In general, the present study provides the detailed insights into the efficient magnetic IONP labeling of A549 lung cancer cells and sheds light on the effects of magnetic labeling on the biological behavior of these cells. The results presented herein provide a new perspective for the application of magnetic IONPs in the cell-targeted labeling and noninvasive tracking behavior of A549 lung cancer cells, as well as offering a promising approach for cell-based lung cancer treatment.
This work was supported by the National Natural Science Foundation of China (No. 314 008 55), the Technological Innovation Incubator Program from Henan University of Technology (No. 201 518), and the Introduced Postdoctoral Talents of Henan University of Technology (No. 150 199).
- 3.Z. Lwin, J.W. Riess, D. Gandara, The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era. J. Thorac. Dis. 5(Suppl 5), S556–S564 (2013)Google Scholar
- 5.P. Dames, B. Gleich, A. Flemmer, K. Hajek, N. Seidl, F. Wiekhorst, D. Eberbeck, I. Bittmann, C. Bergemann, T. Weyh, L. Trahms, J. Rosenecker, C. Rudolph, Targeted delivery of magnetic aerosol droplets to the lung. Nat. Nanotechnol. 2(8), 495–499 (2007). doi: 10.1038/nnano.2007.217 CrossRefGoogle Scholar
- 13.S. Panseri, C. Cunha, T. D’Alessandro, M. Sandri, A. Russo, G. Giavaresi, M. Marcacci, C.T. Hung, A. Tampieri, Magnetic hydroxyapatite bone substitutes to enhance tissue regeneration: evaluation in vitro using osteoblast-like cells and in vivo in a bone defect. PLoS One 7(6), e38710 (2012). doi: 10.1371/journal.pone.0038710 CrossRefGoogle Scholar
- 23.H. Ding, V. Sagar, M. Agudelo, S. Pilakka-Kanthikeel, V.S. Atluri, A. Raymond, T. Samikkannu, M.P. Nair, Enhanced blood-brain barrier transmigration using a novel transferrin embedded fluorescent magneto-liposome nanoformulation. Nanotechnology 25(5), 055101 (2014). doi: 10.1088/0957-4484/25/5/055101 CrossRefGoogle Scholar
- 24.M. Kumar, G. Singh, V. Arora, S. Mewar, U. Sharma, N.R. Jagannathan, S. Sapra, A.K. Dinda, S. Kharbanda, H. Singh, Cellular interaction of folic acid conjugated superparamagnetic iron oxide nanoparticles and its use as contrast agent for targeted magnetic imaging of tumor cells. Int. J. Nanomedicine 7, 3503–3516 (2012)Google Scholar
- 26.R. Namgung, K. Singha, M.K. Yu, S. Jon, Y.S. Kim, Y. Ahn, I.K. Park, W.J. Kim, Hybrid superparamagnetic iron oxide nanoparticle-branched polyethylenimine magnetoplexes for gene transfection of vascular endothelial cells. Biomaterials 31(14), 4204–4213 (2010). doi: 10.1016/j.biomaterials.2010.01.123 CrossRefGoogle Scholar
- 30.X. Wang, Q. Tu, B. Zhao, Y. An, J.C. Wang, W. Liu, M.S. Yuan, S.M. Ahmed, J. Xu, R. Liu, Y. Zhang, J. Wang, Effects of poly(l-lysine)-modified Fe3O4 nanoparticles on endogenous reactive oxygen species in cancer stem cells. Biomaterials 34(4), 1155–1169 (2013). doi: 10.1016/j.biomaterials.2012.10.063 MATHCrossRefGoogle Scholar
- 35.A. Akbarzadeh, M. Samiei, S.W. Joo, M. Anzaby, Y. Hanifehpour, H.T. Nasrabadi, S. Davaran, Synthesis, characterization and in vitro studies of doxorubicin-loaded magnetic nanoparticles grafted to smart copolymers on A549 lung cancer cell line. J. Nanobiotechnology 10, 46 (2012). doi: 10.1186/1477-3155-10-46 CrossRefGoogle Scholar
- 44.M. Neri, C. Maderna, C. Cavazzin, V. Deidda-Vigoriti, L.S. Politi et al., Efficient in vitro labeling of human neural precursor cells with superparamagnetic iron oxide particles: relevance for in vivo cell tracking. Stem Cells 26(2), 505–516 (2008). doi: 10.1634/stemcells.2007-0251 CrossRefGoogle Scholar
- 46.S.J. Soenen, E. Illyes, D. Vercauteren, K. Braeckmans, Z. Majer, S.C. De Smedt, M. De Cuyper, The role of nanoparticle concentration-dependent induction of cellular stress in the internalization of non-toxic cationic magnetoliposomes. Biomaterials 30(36), 6803–6813 (2009). doi: 10.1016/j.biomaterials.2009.08.050 CrossRefGoogle Scholar
- 49.A.H. Koyama, Y. Miwa, Suppression of apoptotic DNA fragmentation in herpes simplex virus type 1-infected cells. J. Virol. 71(3), 2567–2571 (1997)Google Scholar
- 51.S.R. Denmeade, J.T. Isaacs, Programmed cell death (apoptosis) and cancer chemotherapy. Cancer Control 3(4), 303–309 (1996)Google Scholar
- 53.S.Y. Breusegem, R.M. Clegg, F.G. Loontiens, Base-sequence specificity of Hoechst 33258 and DAPI binding to five (A/T)4 DNA sites with kinetic evidence for more than one high-affinity Hoechst 33258-AATT complex. J. Mol. Biol. 315(5), 1049–1061 (2002). doi: 10.1006/jmbi.2001.5301 CrossRefGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.